Logo image of LIFE

ATYR PHARMA INC (LIFE) Stock Fundamental Analysis

NASDAQ:LIFE - Nasdaq - US0021202025 - Common Stock - Currency: USD

1.9  +0.05 (+2.7%)

After market: 1.94 +0.04 (+2.11%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to LIFE. LIFE was compared to 558 industry peers in the Biotechnology industry. Both the profitability and financial health of LIFE have multiple concerns. LIFE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LIFE had negative earnings in the past year.
LIFE had a negative operating cash flow in the past year.
In the past 5 years LIFE always reported negative net income.
LIFE had a negative operating cash flow in each of the past 5 years.
LIFE Yearly Net Income VS EBIT VS OCF VS FCFLIFE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of LIFE (-47.62%) is comparable to the rest of the industry.
LIFE's Return On Equity of -63.85% is in line compared to the rest of the industry. LIFE outperforms 58.06% of its industry peers.
Industry RankSector Rank
ROA -47.62%
ROE -63.85%
ROIC N/A
ROA(3y)-39.44%
ROA(5y)-45.09%
ROE(3y)-49.97%
ROE(5y)-62.48%
ROIC(3y)N/A
ROIC(5y)N/A
LIFE Yearly ROA, ROE, ROICLIFE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

LIFE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIFE Yearly Profit, Operating, Gross MarginsLIFE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

LIFE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LIFE has more shares outstanding
Compared to 5 years ago, LIFE has more shares outstanding
Compared to 1 year ago, LIFE has a worse debt to assets ratio.
LIFE Yearly Shares OutstandingLIFE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
LIFE Yearly Total Debt VS Total AssetsLIFE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -4.12, we must say that LIFE is in the distress zone and has some risk of bankruptcy.
LIFE has a worse Altman-Z score (-4.12) than 61.18% of its industry peers.
LIFE has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
LIFE has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: LIFE outperforms 44.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -4.12
ROIC/WACCN/A
WACC8.87%
LIFE Yearly LT Debt VS Equity VS FCFLIFE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

LIFE has a Current Ratio of 6.07. This indicates that LIFE is financially healthy and has no problem in meeting its short term obligations.
LIFE's Current ratio of 6.07 is fine compared to the rest of the industry. LIFE outperforms 60.66% of its industry peers.
A Quick Ratio of 6.07 indicates that LIFE has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.07, LIFE is doing good in the industry, outperforming 61.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.07
Quick Ratio 6.07
LIFE Yearly Current Assets VS Current LiabilitesLIFE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

LIFE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.93%, which is quite impressive.
The Revenue for LIFE has decreased by -94.34% in the past year. This is quite bad
Measured over the past years, LIFE shows a very negative growth in Revenue. The Revenue has been decreasing by -67.68% on average per year.
EPS 1Y (TTM)37.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.69%
Revenue 1Y (TTM)-94.34%
Revenue growth 3Y-67.68%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 35.04% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 291.57% on average over the next years. This is a very strong growth
EPS Next Y2.52%
EPS Next 2Y9.08%
EPS Next 3Y26.27%
EPS Next 5Y35.04%
Revenue Next Year-19.38%
Revenue Next 2Y375.78%
Revenue Next 3Y505.83%
Revenue Next 5Y291.57%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LIFE Yearly Revenue VS EstimatesLIFE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
LIFE Yearly EPS VS EstimatesLIFE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LIFE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LIFE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIFE Price Earnings VS Forward Price EarningsLIFE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIFE Per share dataLIFE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

LIFE's earnings are expected to grow with 26.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.08%
EPS Next 3Y26.27%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LIFE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATYR PHARMA INC

NASDAQ:LIFE (6/4/2024, 8:12:25 PM)

After market: 1.94 +0.04 (+2.11%)

1.9

+0.05 (+2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-02 2024-05-02/amc
Earnings (Next)08-07 2024-08-07/amc
Inst Owners69.81%
Inst Owner Change23.59%
Ins Owners12.06%
Ins Owner Change0%
Market Cap129.87M
Analysts81.82
Price Target25.09 (1220.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.74%
Min EPS beat(2)-2.98%
Max EPS beat(2)4.45%
EPS beat(4)3
Avg EPS beat(4)9.32%
Min EPS beat(4)-2.98%
Max EPS beat(4)22.57%
EPS beat(8)6
Avg EPS beat(8)12.77%
EPS beat(12)7
Avg EPS beat(12)6.02%
EPS beat(16)10
Avg EPS beat(16)4.78%
Revenue beat(2)1
Avg Revenue beat(2)475.98%
Min Revenue beat(2)-100%
Max Revenue beat(2)1051.96%
Revenue beat(4)1
Avg Revenue beat(4)193.76%
Min Revenue beat(4)-100%
Max Revenue beat(4)1051.96%
Revenue beat(8)2
Avg Revenue beat(8)641.07%
Revenue beat(12)2
Avg Revenue beat(12)394.04%
Revenue beat(16)4
Avg Revenue beat(16)382.04%
PT rev (1m)8.85%
PT rev (3m)10.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.98%
EPS NY rev (1m)2.81%
EPS NY rev (3m)-7.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-84.63%
Revenue NY rev (3m)-95.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 220.87
P/FCF N/A
P/OCF N/A
P/B 1.54
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.01
BVpS1.24
TBVpS1.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.62%
ROE -63.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.44%
ROA(5y)-45.09%
ROE(3y)-49.97%
ROE(5y)-62.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 432.17%
Cap/Sales 507.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.07
Quick Ratio 6.07
Altman-Z -4.12
F-Score1
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)486.58%
Cap/Depr(5y)301.47%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.69%
EPS Next Y2.52%
EPS Next 2Y9.08%
EPS Next 3Y26.27%
EPS Next 5Y35.04%
Revenue 1Y (TTM)-94.34%
Revenue growth 3Y-67.68%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-19.38%
Revenue Next 2Y375.78%
Revenue Next 3Y505.83%
Revenue Next 5Y291.57%
EBIT growth 1Y-25.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.85%
EBIT Next 3Y43.39%
EBIT Next 5Y48.12%
FCF growth 1Y-54.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.21%
OCF growth 3YN/A
OCF growth 5YN/A